{"id":28011,"date":"2024-03-19T14:50:42","date_gmt":"2024-03-19T19:50:42","guid":{"rendered":"https:\/\/myeloma.ca\/?p=28011"},"modified":"2024-03-19T14:50:44","modified_gmt":"2024-03-19T19:50:44","slug":"schema-therapeutique-utilisation-des-ressources-en-soins-de-sante-et-fardeau-des-symptomes-chez-les-patients-ayant-ete-exposes-a-trois-categories-de-traitement-pour-le-myelome-multiple-une-etude-de","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/03\/19\/schema-therapeutique-utilisation-des-ressources-en-soins-de-sante-et-fardeau-des-symptomes-chez-les-patients-ayant-ete-exposes-a-trois-categories-de-traitement-pour-le-myelome-multiple-une-etude-de\/","title":{"rendered":"Sch\u00e9ma th\u00e9rapeutique, utilisation des ressources en soins de sant\u00e9 et fardeau des sympt\u00f4mes chez les patients ayant \u00e9t\u00e9 expos\u00e9s \u00e0 trois cat\u00e9gories de traitement pour le my\u00e9lome multiple : une \u00e9tude de cohorte bas\u00e9e sur une population\u00a0(en anglais seulement)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Cette \u00e9tude vise \u00e0 d\u00e9crire les sch\u00e9mas th\u00e9rapeutiques, les r\u00e9sultats, l\u2019utilisation des ressources en soins de sant\u00e9 et le fardeau des sympt\u00f4mes chez les patients atteints d\u2019un my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont \u00e9t\u00e9 expos\u00e9s \u00e0 trois cat\u00e9gories de traitement et re\u00e7oivent un traitement ult\u00e9rieur.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S215226502400065X?dgcid=author\" target=\"_blank\" rel=\"noopener\" title=\"\">En savoir plus&#8230;<\/a>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cette \u00e9tude vise \u00e0 d\u00e9crire les sch\u00e9mas th\u00e9rapeutiques, les r\u00e9sultats, l\u2019utilisation des ressources en soins de sant\u00e9 et le fardeau des sympt\u00f4mes chez les patients atteints d\u2019un my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont \u00e9t\u00e9 expos\u00e9s \u00e0 trois cat\u00e9gories de traitement et re\u00e7oivent un traitement ult\u00e9rieur.\u00a0 En savoir plus&#8230;\u00a0<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-28011","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=28011"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28011\/revisions"}],"predecessor-version":[{"id":28012,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28011\/revisions\/28012"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=28011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=28011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=28011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}